Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2021)
Outlook Therapeutics (OTLK) reported Gains from Sales and Divestitures of $1.8 million for Q4 2021, little changed year-over-year from $1.8 million in Q4 2020, and little changed quarter-over-quarter from $1.8 million in Q2 2021.
Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2021) Analysis & Trends
Outlook Therapeutics (OTLK) has 4 years of Gains from Sales and Divestitures data on file, last reported at $1.8 million in Q4 2021.
- Gains from Sales and Divestitures for Q4 2021 came in at $1.8 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.8 million (changed 0.0% YoY), and the FY2020 annual result was $109.0, down 97.32% from the prior year.
- Gains from Sales and Divestitures steadied at $1.8 million in Q4 2021 per OTLK's latest filing, from $1.8 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $1.8 million in Q4 2020 and troughed at $109.0 in Q4 2019.
- A 4-year average of $735460.2 and a median of $54715.0 in 2018 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 1661536.7% in 2020 and fell as far as 97.32% in 2020.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $105361.0 in 2018, then plunged by 99.9% to $109.0 in 2019, then soared by 1661536.7% to $1.8 million in 2020, then changed by 0.0% to $1.8 million in 2021.
- Business Quant data shows OTLK's Gains from Sales and Divestitures at $1.8 million in Q4 2021, $1.8 million in Q2 2021, and $1.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Outlook Therapeutics | 63.14 Mn | 55.40 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.81 Mn |
| Dec 31, 2021 | 1.81 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 1.81 Mn |
| Mar 31, 2021 | 1.81 Mn |
| Dec 31, 2020 | 1.81 Mn |
| Dec 31, 2020 | 1.81 Mn |
| Sep 30, 2020 | 109.00 |
| Sep 30, 2020 | 109.00 |
| Jun 30, 2020 | 109.00 |
| Jun 30, 2020 | 109.00 |
| Mar 31, 2020 | 109.00 |
| Mar 31, 2020 | 109.00 |
| Dec 31, 2019 | 109.00 |
| Dec 31, 2019 | 109.00 |
| Sep 30, 2019 | 4,069.00 |
| Sep 30, 2019 | 4,069.00 |
| Sep 30, 2018 | 105,361.00 |
| Sep 30, 2018 | 105,361.00 |